Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

The genetic architecture of psychiatric disorders is complex. Psychiatric disorders display strong heritability, as demonstrated in family and twin genetic studies. Recent large-scale, genome-wide studies have identified associations of psychiatric disorders with several common genetic variants, rare de novo copy number variants (CNVs), and loss of function or missense mutations. However, these findings explain only a small proportion of the heritability of psychiatric disorders. The missed or unexplained heritability could be attributed to complex genetic architecture and interactions between genetic and environmental factors. In addition to heritable genetic factors, the idea that de novo somatic variations are involved in central nervous system disorders is gaining traction.

Somatic mosaicism, the phenomenon whereby not all cells of the human body have identical DNA sequence, occurs as part of the normal developmental process. Retrotransposon activity, replication errors during rapid mitotic expansion of neurons during fetal brain development, and electrophysiological activity of the neurons have been implicated in the generation of somatic variations. Recent studies suggest that such variations might accumulate throughout the lifespan and be widespread in the brain.

Somatic genomic variations could occur in the form of single nucleotide variants (SNVs), copy number variants (CNVs), structural variants (SVs), or retrotransposon insertions. Such variations could alter epigenetic and transcriptome patterns, creating functional diversity among brain cells which could result in alteration of cell signaling pathways and neural circuit function leading to behavioral perturbations and disease. Somatic mosaicism has been studied extensively in the context of cancer, but this work has only recently begun to focus on brain disorders, particularly neurodevelopmental disorders. For example, in hemimegalencephaly (HMG), mutations in ATK3, PI3KCA, and mTOR genes in as few as 8% of the brain cells were found to result in cortical perturbations in an entire cerebral hemisphere. Recent technological progress in single-cell genome sequencing has made it possible for researchers to explore somatic variations at a single-cell level. Through such single-cell approaches, studies have identified several somatic Long Interspersed Nuclear Elements (LINE-1) insertions that occur in neural cell lineages during normal brain development.

Although there is increasing evidence of somatic mosaicism in the brain, the extent of such variation and its functional significance in normal brain development and in psychiatric disorders remain poorly understood. Elucidating the architecture of genetic perturbations in somatic cells of normal and diseased brains may provide new insights into genetic susceptibility of complex psychiatric disorders and lead to the identification of novel therapeutic targets.

The key objective of this FOA is to encourage interdisciplinary collaborative applications aimed at understanding the role of somatic mosaicism in the development of neuropsychiatric disorders. Preference will be given to projects which are proposed by a highly interactive and synergistic team of investigators with complementary expertise. Successful applications will include expertise in genetics, neuro-developmental biology, psychiatry, high-throughput single-cell analysis, whole genome sequence analysis, computational bioinformatics, and or other fields relevant to the FOA. All awards supported under this FOA and the companion FOA (PAR-14-173) will be governed by a Brain Somatic Mosaicism (BSM) Network Steering Committee to accelerate scientific progress through the coordination of research strategies, analytical methods and genomic data.

An integral part of this FOA is identifying somatic variations in human brain and characterizing their role in one or more psychiatric disorders. Under the scope of this FOA, specific areas of research interest include, but are not limited to the following:

• Identify, characterize and validate the frequency and distribution of a range of somatic variations, including CNVs, SNVs, SVs, and retrotransposon insertions in different cell types, across brain regions, from diseased and healthy control brains.

• Identify whether somatic variations are differentially represented in diseased brains compared to healthy brains, with reference to the extent, frequency, location, and types of somatic variations, as well as the brain regions and cell types in which they occur.

• Apply state-of-the-art methods to prioritize somatic variants in coding and non-coding regions of the genome, based on their functional relevance to brain and psychiatric disorders.

• Identify whether and how such somatic variants interact with genes and gene networks reported to be associated with psychiatric disorders (e.g., using computational approaches).

• Trace the origin of such prioritized somatic variations across a range of developmental stages to identify how and when the variations occurred and assess their effects on downstream neurodevelopmental events.

• Pursue follow-up functional characterization of prioritized somatic variants through a variety of approaches, such as transcriptome analysis, epigenetic profiling, engineering somatic mutations in neural progenitor cells or iPSC lines to assess phenotypes, or by using other novel in vitro or in vivo model systems.

Applications submitted to this FOA should include the following elements: 1) comprehensive characterization and comparison of somatic variations in healthy control and diseased brains, and 2) determination of functional roles for these variations in psychiatric disorders. Since the primary focus of this FOA is to identify and characterize somatic variations in diseased human brains, the projects could utilize a phased approach. For example, the initial focus of the applications might be discovery of somatic variations across human brain; subsequent aims might focus on functional follow-up experiments to investigate the role of somatic mosaicism in the development of psychiatric disorders.

Research applications could explore the extent of somatic variations across neuronal cell types and lineages, from different brain regions, and/or for one or more psychiatric disorders. For example, one approach might be to combine state-of-the-art genomic, computational, single-cell and other relevant approaches to rapidly characterize and generate a high resolution map of different types of somatic variations across multiple brain regions implicated in the pathophysiology of psychiatric disorders.

Applications are encouraged to apply unbiased genomic approaches to evaluate somatic mosaicism using appropriate human brain samples from patient populations to correlate findings with psychiatric disorders. Comprehensive assessments could include identifying a range of somatic variations in different cell types or cell lineages, across brain regions in a large number of individuals covering one or more lifetime periods. For initial discovery of somatic genomic variations, applicants are encouraged to propose studies using brain samples from human patient populations, rather than induced pluripotent stem cell (iPSC) lines or model organisms as primary source. However, iPSC cell lines or animal models could be employed for functional follow-up analysis.

To the extent possible, investigators are encouraged to leverage existing large-scale, genome-wide data sets and brain sample collections from publicly available resources, including but not limited to Brainspan, The Genotype-Tissue Expression Project (GTEx), NIH NeuroBiobank, CommonMind Project, and Autism Tissue Program (ATP).

This FOA should be used when two or more collaborating sites are essential to complete the proposed research. It is required that Research Strategy must be identical across linked collaborative U01 applications, with the exception of a short section describing specific function of each application under "elements unique to that site." For a linked set of collaborative U01 applications, each application must have its own Program Directory/Principal Investigator (PD/PI) and the program must provide a mechanism for cross-site coordination, quality control, data and sample sharing among BSM Network members, as appropriate, database management, statistical analysis, and reporting.

All awards supported under this FOA and the companion FOA (PAR-14-173) will be governed by the Brain Somatic Mosaicism (BSM) Network Steering Committee. Through the BSM Network Steering Committee, members are encouraged to address gaps in our understanding of the prevalence and distribution of somatic variations in the human brain, and their role in the development of neuropsychiatric disorders. The BSM Network Steering Committee members will 1) share ideas, approaches, technologies and methods, 2) identify synergies across projects, 3) coordinate across projects for data standardization and validation, 4) facilitate immediate data and resource sharing among the BSM Network members as appropriate, 5) set overall milestones for the BSM Network, and 6) guide and evaluate progress and direction of the BSM Network. U01 applicants applying for future submission dates under this FOA and the companion FOA (PAR-14-173) will also be governed by the BSM Network Steering Committee and are expected to align their research with the overall BSM Network research priorities.

Applicants are strongly encouraged to consult the appropriate Scientific/Research Contacts, listed in Section VII, to discuss the structure of the collaborations, and research topics of interest for alignment of their proposed work with the Program objectives and the BSM Network research priories.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education

• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions

• Historically Black Colleges and Universities (HBCUs)

• Tribally Controlled Colleges and Universities (TCCUs)

• Alaska Native and Native Hawaiian Serving Institutions

• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)

• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses

• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments

• County Governments

• City or Township Governments

• Special District Governments

• Indian/Native American Tribal Governments (Federally Recognized)

• Indian/Native American Tribal Governments (Other than Federally Recognized)

• Eligible Agencies of the Federal Government

• U.S. Territory or Possession

Other

• Independent School Districts

• Public Housing Authorities/Indian Housing Authorities

• Native American Tribal Organizations (other than Federally recognized tribal governments)

• Faith-based or Community-based Organizations

• Regional Organizations

• Non-domestic (non-U.S.) Entities (Foreign Institutions)

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.

• System for Award Management (SAM) (formerly CCR) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

This FOA supports linked Cooperative Agreement (U01) applications. Multiple PDs/PIs are allowed on any single application. Because the FOA already supports a team approach between groups of experts across sites and collaborating applications, the designation of multiple PDs/PIs on a single application may be less likely to apply. PD(s)/PI(s) from each linked application should NOT be designated as multiple PDs/PIs on each application of a collaborative set.

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.

• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

In addition, the NIH will not accept a resubmission (A1) application that is submitted later than 37 months after submission of the new (A0) application that it follows. The NIH will accept submission:

• To an RFA of an application that was submitted previously as an investigator-initiated application but not paid;

• Of an investigator-initiated application that was originally submitted to an RFA but not paid; or

• Of an application with a changed grant activity code.

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed activity

• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)

• Names of other key personnel

• Participating institution(s)

• Number and title of this funding opportunity

The letter of intent should be sent to:

Geetha Senthil Ph.D.
Office of Genomics Research Coordination
National Institute of Mental Health (NIMH)
6001 Executive Boulevard, Room 7200
Bethesda, MD 20892-9643
Rockville, MD 20852 (for courier/express mail service)
Telephone: 301-402-0754
Fax: 301-402-4740
Email: [email protected]

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

All instructions in the SF424 (R&R) Application Guide must be followed. With the following additional instructions:

Descriptive Title of Applicant's Project: To allow NIH to identify a group of applications as a related set of collaborative U01s, the titles for each U01 in the set must have the following format: a 1/N indicator + Identical title (e.g., 1/6-Multisite Comparison of Drug A vs. Drug B for Treatment of Disorder X , where the 1/6 means this is site 1 of 6 sites in the set. The other sites will be labeled 2/6, 3/6, etc.) Titles may not exceed 80 characters in length, including the tag, e.g., 1/6, at the beginning of the title.

Cover Letter Attachment: The Cover Letter is one pdf file only. The following collaborative information is required in the Cover Letter: a listing of all the applications that are a part of the set of collaborative U01s being submitted, including for each: 1) the PD/PI(s) name(s), 2) the Title (including the tag, e.g., 1/6 ), and 3) the Applicant Institution. Each site must submit an identical listing.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed. with the following additional information:

Facilities and Other Resources: Applicants are advised that the Facilities and Other Resources section should address not only physical resources, but also the intellectual and collaborative resources for executing the project. Instructions for this section include the following:

Describe how the scientific environment in which the research will be done contributes to the probability of success (e.g., institutional support, physical resources, and intellectual rapport). In describing the scientific environment in which the work will be done, discuss ways in which the proposed studies will benefit from unique features of the scientific environment.

For linked applications from multiple sites, each application must describe the resources available at that site. This should describe the individual applicant site and it is expected that this section of the application will be different in each of the linked applications.

Other Attachments: Linked applications must provide an identical Project Management Plan across sites submitted as a single pdf attachment, with the title "Project Management and Collaboration Plan."

The Project Management and Collaboration Plan must provide detailed description of how different elements of the project would operate in a synergistic and integrated manner, leadership structure and data coordination plan. The following guidelines and framework must be followed in developing this plan:

• Demonstrate how the proposed collaborative work will address questions that would be difficult to answer with data from a single site.

• Describe how scientific research procedures will be integrated across sites within a project, and cross-site comparability of training and procedures to assure reliability and quality control.

• Describe how data coordination will occur across linked applications including information about processes for joint decision-making regarding research activities across sites.

• Include plans for ensuring: replication, comprehensive transparency of data reporting/sharing among the Network members, rapid access to data and analytical resources by all the performance sites as appropriate.

• Include a plan for ensuring experimental rigor and control of bias (e.g., with sample size estimation, data handling) as appropriate across linked applications.

• Describe plans for maintenance of close collaboration and effective communication among members of the group through group meetings, including frequency and types of contact between participating researchers, and documenting and disseminating group meeting proceedings.

• Provide description of the leadership structure across linked applications describing overall managerial and administrative responsibilities, specification of leadership roles, and responsibilities for specialized subparts of the research plan.

• Include a plan for publication and authorship rights; and a process for arbitrating disagreements on publication and other issues; completion of the research project should a key member leave the Group, including plans to replace the PD/PI if needed.

• Include a statement that awardees will agree to the "Cooperative Agreement Terms and Conditions of Award" in Section VI.2. "Award Administration Information."

All instructions in the SF424 (R&R) Application Guide must be followed. It is expected that the projects will include synergistic research teams comprised of outstanding scientists from diverse scientific disciplines with expertise in neurodevelopmental biology, genetics, psychiatry, computational bioinformatics, analysis of genome-wide data, psychiatry, high-throughput single-cell technologies, and/or other fields relevant to the FOA. As appropriate, Senior/Key Personnel should demonstrate their experience and expertise in these areas.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Specific Aims: The collaborative mechanism requires an Overview section as part of the specific aims attachment. This attachment must provide: 1) an overall rationale for applying as a collaborative study; 2) outline the role of each site and how they will contribute to achieve the FOA objectives; 3) Specific Aims of the collaborative project. This Specific Aims attachment must be identical in each of the applications that are linked together in a collaborative U01 set.

Research Strategy: Applications from each site must contain a Research Strategy that clearly describes those aspects of the project that are common to all sites of the collaboration.

The Research Strategy must be identical across linked collaborative U01 applications with the exception of the section under the header "Elements Unique to This Site." All variations in the Research Strategy between sites, no matter how minor, should be highlighted in a subsection of the Research Strategy with the heading "Elements Unique to This Site" (estimated to be no more than 1 page of the Research Strategy Section). In this subsection PDs/PIs should describe, for example, how the research site has a unique role in the collaboration, such as data coordination, statistical analyses, etc. Any site that contracts out some portions of this work should list this fact under "Elements Unique to This Site," and provide a full description of the nature, purpose and oversight of this contractual arrangement.

Applications must conform with current guidelines taking care to address important elements related to Significance, Approach, and Innovation. As a part of the Research Strategy section, applicants are requested to clearly address the following aspects:

• Include a detailed plan for the following elements: a) identification and comprehensive assessment and comparisons of the full spectrum of somatic genomic variations in healthy and diseased cases using global mapping approaches across different brain regions from multiple individuals, and b) functional follow-up experiments to determine the role of somatic variations.

• Provide a rationale for the choice of cell-types, brain regions, number of samples, technologies, data collection, validation strategies, and functional readouts for elucidating the role of somatic genetic perturbations in the pathophysiology of psychiatric disorders. Applicants are encouraged to propose use of appropriate phenotypically well-characterized high quality human brain samples from patient populations for initial discovery of somatic genomic variations to correlate findings with psychiatric disorders. For initial discovery effort, induced pluripotent stem cell (iPSC) lines or model organisms should not be used as primary source. However, iPSC cell lines or animal models may be employed for functional follow-up analysis.

• Include: 1) utilization of a sufficient number of patient-derived samples to achieve appropriate statistical power; 2) robust and well-validated cost effective techniques and methods; and 3) datasets and functional assays relevant to pathophysiology of psychiatric disorders.

• Propose use of unbiased genomic approaches and state-of-the-art technologies using appropriate cells or tissues derived from patient populations and controls to correlate findings with the pathophysiology of psychiatric disorders. Such technologies should be scalable and high-throughput for assessing somatic variations at high resolution (e.g. rare somatic mutations at single-cell level).

• Propose a detailed plan for identification, validation and confirmation of predicted somatic variants including novel rare somatic variants

• Describe the capabilities for sequence production, quality control (QC), storage, data analysis, and annotation accuracy to distinguish between sequencing errors and real polymorphisms.

• A Timeline and Milestones Section must be included in the Research Strategy section of the application. Milestones should be well described, specific, measurable, and should include scientifically justified benchmarks. Milestones may include the following: tissue procurement and processing; generation of genomic datasets for identification and comparisons of full spectrum of somatic variations in diseased and control (healthy) brains; computational analysis; validation and quantification of such variations; follow-up functional analysis of the prioritized somatic variations. The milestones should be regarded as criteria for evaluating the progress and direction of the Research Project(s) and should not be just a restatement of the specific aims.

• Investigators are encouraged to leverage existing large-scale, genome-wide data sets and brain sample collections from publicly available resources, including but not limited to Brainspan, The Genotype-Tissue Expression Project (GTEx), NIH NeuroBiobank, CommonMind Project, and Autism Tissue Program (ATP).

Letters of Support: Applications should include signed letters of support confirming access to adequate brain tissue samples from psychiatric cases as well as healthy controls.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide, with the following modification:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

• All applicants are expected to provide a comprehensive plan for rapid and timely release of resulting data, biomaterials, and tools to the wider scientific community through public database such as database of Genotypes and Phenotypes (dbGaP), and NIMH Genetics Resource and Repository (http://nimhgenetics.org), in accordance with NIH sharing policies. Per NIMH policy (NOT-MH-13-002), grantees who generate or use human subject-derived reprogrammed cells are expected to submit relevant source cells (e.g., fibroblasts, olfactory epithelial cells, blood) and reprogrammed derivatives (e.g., induced pluripotent stem cells/iPSCs or other renewable cell lines) to the NIMH Genetics Resource and Repository.

Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.

When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.

Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.

In order to expedite review, applicants are requested to notify the NIMH Referral Office by email at [email protected] when the application has been submitted. Please include the FOA number and title, PD/PI name, and title of the application.

Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A), OR $500,000 or more in direct costs for the COMBINED budgets across the linked applications, must contact NIH program staff at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide. For Collaborative sets where the combined budgets are at or above $500,000, each application should include their letter of approval from the NIMH in the Cover Letter component, even if an individual application budget is below $500,000.

Use of Common Data Elements in NIH-funded Research

NIH encourages the use of common data elements (CDEs) in basic, clinical, and applied research, patient registries, and other human subject research to facilitate broader and more effective use of data and advance research across studies. CDEs are data elements that have been identified and defined for use in multiple data sets across different studies. Use of CDEs can facilitate data sharing and standardization to improve data quality and enable data integration from multiple studies and sources, including electronic health records. NIH ICs have identified CDEs for many clinical domains (e.g., neurological disease), types of studies (e.g. genome-wide association studies (GWAS)), types of outcomes (e.g., patient-reported outcomes), and patient registries (e.g., the Global Rare Diseases Patient Registry and Data Repository). NIH has established a Common Data Element (CDE) Resource Portal" (http://cde.nih.gov/) to assist investigators in identifying NIH-supported CDEs when developing protocols, case report forms, and other instruments for data collection. The Portal provides guidance about and access to NIH-supported CDE initiatives and other tools and resources for the appropriate use of CDEs and data standards in NIH-funded research. Investigators are encouraged to consult the Portal and describe in their applications any use they will make of NIH-supported CDEs in their projects.

Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the project address the objectives of the FOA to transform our knowledge of the potential role of somatic genomic variations in brain function and pathophysiology of psychiatric disorders? Are the plans sufficiently bold to constitute a substantial advance in the ability to characterize somatic genomic variations at high resolution? Does the proposed work have a strong likelihood of revealing the extent of genomic mosaicism in human brain and its impact on brain dysfunction related to psychiatric disorders?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Do the PD(s)/PI(s) have prior experience with coordinating collaborative research? Do the investigators have documented experience in genetics, neuro-development, psychiatry, analysis of high-throughput sequencing data, computational bioinformatics, single cell analysis, and other relevant fields appropriate to this FOA? Is there complementary and synergistic expertise across the consortium? Will the leadership plan optimize the management of a milestone-driven, multidisciplinary project?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Will the data arising from these studies support the identification of a full spectrum of human brain-specific somatic genomic variations in patient populations to understand their role in brain function and psychiatric disorders? Are there innovative strategies for analysis of genomic data that will lead to the development of new paradigms for analyzing somatic variations at high resolution? Does the application represent an innovative technological solution which overcomes current scientific or technical barriers?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Does the project employ unbiased genomic approaches using appropriate cells or tissues derived from patient populations and controls to correlate findings with the pathophysiology of psychiatric disorders? Do the applicants provide an adequate rationale for choice of cell-types, brain regions, number of samples, technologies, validation strategies, and functional readouts for elucidating the role of somatic genetic perturbations in the pathophysiology of psychiatric disorders? Is the primary focus of the application discovery using global mapping approaches across the genome across different brain regions from multiple individuals? Does the proposed project adequately address issues of statistical power? Are the proposed samples of sufficiently high quality to provide high quality results? Are there clear plans for validation of novel rare somatic variants? Does the project propose to conduct comprehensive assessment and comparison of the full spectrum of somatic variations across brain regions in diseased and healthy brains? Does the project propose realistic timeline and milestones? Are key technical barriers and dependencies identified? Is sufficient information provided about sample size, choice of cell types and brain regions, and demographics, including an inventory of existing brain samples and phenotypic measures? If new data collection is proposed, is the justification appropriate and compelling?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Project Management and Collaboration

Does the research plan justify the need for a collaborative multi-site project using this FOA? Are sufficient and feasible mechanisms in place to ensure collaboration across sites to achieve scientific integration of research procedures, overall managerial and administrative responsibilities, appropriate quality control and reliability assurance, and planning for data management, analysis and reporting of results? Does the application description address data coordination across linked applications? Does the application provide a description of the leadership structure across the linked applications? Are there adequate plans for shared decision making among PDs/PIs with regard to personnel, changes in research activities? Does the description address frequency and type of contact between participating researchers; specification of leadership roles across linked applications; and a description of whether particular individuals or sites will coordinate specialized subcomponents of the research plan? Does the application describe processes for joint decision-making regarding research activities and publication, as well as procedures for resolving disagreements and grievance?

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Children

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

Renewals

Not Applicable

Revisions

For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMH, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

• May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

• Will receive a written critique.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications . Following initial peer review, recommended applications will receive a second level of review by the National Advisory Mental Health Council . The following will be considered in making funding decisions:

• Scientific and technical merit of the proposed project as determined by scientific peer review.

• Availability of funds.

• Relevance of the proposed project to program priorities.

• Adequacy of the data sharing plan as appropriate.

• The adequacy of the proposed team of investigators in terms of their complementary expertise in genetics, neurodevelopmental biology, psychiatry, high-throughput single-cell analysis, whole genome sequence analysis, computational bioinformatics, and or other fields relevant to the FOA as well as the fit of the team of investigators.

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

All awardees under this FOA and the companion FOA (PAR-14-173) will be governed by the BSM Network Steering Committee composed of the PDs/PIs of each project within the network, NIMH Project Scientist(s), and the NIMH Program Officer to assist in motoring and developing scientific content and direction of the program.

• Define objectives, approaches and to plan and conduct the proposed research and assume responsibility and accountability to the applicant organization and to the NIMH for performance and proper conduct of all research supported in this initiative, in accordance with the Terms and Conditions of Award.

• Coordinate and attend at least monthly BSM Network Steering Committee meetings. The PD/PIs will be responsible for preparing concise proceedings or minutes (two or three pages), which will be delivered to the members of the Network within one week of the meeting.

• Provide leadership in thought, ideas, and actions; working with the organization, structure, and advisors of the network.

• Accept close interaction with and participation of NIH staff in aspects of management of the network; cooperating and assisting in implementing the recommendations of the Steering Committee to facilitate coordination amongst all the U01 grantees under this FOA.

• Coordinate and collaborate with other national and international groups that may be generating relevant genomic datasets

• Communicate and publish major findings by the BSM Network members in a timely manner. Publication or oral presentation of work done under this agreement will be accompanied by appropriate acknowledgment of NIMH support, including the assigned cooperative agreement award number.

• Ownership of all analytic tools, protocols and assays developed during the course of the research rests with the respective PI(s) who generated them.

• The Awardee Institution and/or Research Project Leader's Institution will retain primary custody of and have primary rights to data as specified under the NIMH approved data and research resource sharing plans (described above). These plans should include sharing clinical and genotypic data with the NIMH Center for Collaborative Genomic Studies, genotype-phenotype data with the database of Genotypes and Phenotypes (dbGaP), and/or clinical and associated genotype and phenotype data associated with autism spectrum disorders to the National Database for Autism Research (NDAR), as appropriate. The Government, via the NIMH Project Scientist(s), will have access to data generated under this cooperative agreement and may periodically review the data consistent with current DHHS, PHS, and NIH policies. Timely publication of major findings by the Group members is strongly encouraged. Publication or oral presentation of work done under this agreement will be accompanied by appropriate acknowledgment of NIMH support, including the assigned cooperative agreement award number.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

The NIMH Project Scientist (or designated alternate in the event the Project Scientist is not available) will have substantial programmatic/scientific involvement:

• Coordinate and facilitate the interactions among the research teams supported under this FOA.

• Serve as a resource with respect to other ongoing NIH activities that may be relevant to this effort and providing expert advice to the awardees on specific scientific and/or analytic issues.

• Assist in the design, development, and coordination of the different stages of the study within their role as a participant on the BSM Network Steering Committee.

• Review analysis plans to ensure that they are within the scope of this effort and consistent with the results of peer review.

• The Project Scientist will retain the option to recommend additional research endeavors or update the timeline and milestones of the project as necessary within the constraints of the approved research and negotiated budget. To help carry out these duties, the Project Scientist may consult with non-NIH experts in the field.

• Coordinate and review with the assistance of the PD(s)/PI(s) the timeline for processing procedures, data submission and integration, and distribution to approved investigators.

• Serve as a voting member(s) of the BSM Network Steering Committee.

• Participate in BSM Network Steering Committee meetings and conference calls.

In addition, an NIMH Program Officer has usual stewardship responsibility for monitoring the conduct and progress of the project to ensure milestones are accomplished in accordance with the timeline. The Program Officer carries primary responsibility for periodic review and approval of the study protocol in relation to stated recommendations regarding continuance of the project, receives all required reports and determines that satisfactory progress is being made, and attends the BSM Network Steering Committee meetings as a non-voting participant. The Program Officer negotiates throughput, quality control, validation, and cost goals with the awardees as necessary and suggests reprogramming efforts, including options to modify projects/programs when certain objectives of this FOA are not being met.

Participation of NIH Intramural Scientists:

An NIH intramural scientist may participate as a collaborator or consultant. However, an Intramural scientist may not receive salary, equipment, supplies, or other remuneration from awards resulting from this FOA. The Intramural scientist must obtain written approval of his/her NIH Institute Scientific Director for the amount of resources that may be allocated to the project. The approval must also specify that the conduct of the project will comply with the DHHS regulations for research involving human subjects (if applicable) and with the PHS policy on vertebrate animal research. The participation of an intramural scientist is independent of and unrelated to the role of the NIMH Project Scientist. The involvement of Intramural scientists needs to be consistent with NIH Policy and all applicable federal laws and regulations: http://www1.od.nih.gov/oir/sourcebook/ethic-conduct/ethical-conduct-toc.htm.

Areas of Joint Responsibility include:

All awardees under this FOA and the companion FOA (PAR-14-173) will be governed by the BSM Network Steering Committee composed of the PDs/PIs of each grant, NIMH Project Scientist(s), and the NIMH Program Officer to assist in motoring and developing scientific content and direction of the program. The BSM Network Steering Committee will select, by majority vote, a Chair from among the PD/PIs for a two-year term.

• The BSM Network Steering Committee will:

• Ensure synergistic functioning and coordination across grants supported under this FOA.

• Assist in motoring and developing scientific content and direction of the BSM Network.

• Identify synergies across projects.

• Coordinate across projects for data standardization and validation

• Share data and resource among the BSM Network members and with the broader scientific community in a timely manner as per the data sharing plan and the BSM Steering Committee recommendations as appropriate.

• Set research priorities and milestones for the overall BSM Network.

• Guide and evaluate the progress and direction of the research conducted by the awardees.

• Establish timeline of expected progression of the research activities

• Form appropriate subgroups to develop uniform procedures and practices, for example for data quality measures and assessment, nomenclature and annotation conventions for data depositions, and so forth.

• Form appropriate subgroups to collaborate closely on selection and generation of appropriate cell/tissue specimens. In these cases, for example, common policies, uniform practices (as needed), and data exchange will be adopted the BSM Network awardees to enable harmonization and eliminate duplication/overlap.

• Coordinate and attend monthly meetings of the BSM Network Steering Committee to review progress and identify emerging opportunities for strategic partnerships, decide optimal research approaches and protocol designs as warranted.

It is expected that decisions made or actions taken by the BSM Network Steering Committee will be by consensus, or majority vote when needed; the contact PI of each award will have one vote, with NIMH Project Scientist (or alternate) having one vote. The NIMH Program Officer will not have a vote. All the BSM Network Steering Committee members will attend in person at least an annual meeting to discuss progress and share research findings. Outside consultants/experts may be asked to participate in BSM Network Steering Committee meetings and discussions, but not have a vote on committee decisions. Membership on the BSM Network Steering Committee becomes effective upon issuance of the Notice of Grant Award. The PIs agree to accept the close coordination, cooperation, and participation of a NIMH Project Scientist and the Steering Committee to facilitate coordination amongst all the U01 awards under this initiative.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the BSM Network Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Finding Help Online: http://grants.nih.gov/support/index.html
Email: [email protected]

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: [email protected]

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone: 301-710-0267
Email: [email protected]

Geetha Senthil Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-402-0754
Email: [email protected]

David Armstrong, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-3534
Email: [email protected].

Terri Jarosik
National Institute of Mental Health (NIMH)
Telephone: 301-443-3858
Email: [email protected]

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.